Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Stock Short Interest Rises 92.5%

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) saw a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 12,377 shares, a growth of 92.5% from the October 15th total of 6,429 shares. Based on an average daily trading volume, of 37,998 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.2% of the company’s shares are short sold.

Hedge Funds Weigh In On Neuphoria Therapeutics

A hedge fund recently bought a new position in Neuphoria Therapeutics stock. Merck & Co. Inc. purchased a new position in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 10,027 shares of the company’s stock, valued at approximately $43,818. Neuphoria Therapeutics makes up 0.0% of Merck & Co. Inc.’s investment portfolio, making the stock its 13th largest holding. Merck & Co. Inc. owned approximately 0.19% of Neuphoria Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on NEUP shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday, August 27th. Wall Street Zen raised Neuphoria Therapeutics to a “hold” rating in a research report on Saturday, July 25th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $7.00.

Neuphoria Therapeutics Trading Down 1.2%

Neuphoria Therapeutics stock traded down $0.03 during mid-day trading on Friday, hitting $2.55. The company had a trading volume of 14,972 shares, compared to its average volume of 36,892. Neuphoria Therapeutics has a 12 month low of $2.49 and a 12 month high of $5.53. The company has a market capitalization of $13.80 million, a PE ratio of -0.41 and a beta of 0.77. The stock’s 50 day moving average price is $3.37 and its two-hundred day moving average price is $4.09.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions. The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies. Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.